Side Effects of Psychotropic Medications Experienced by a Community Sample of People Living With Severe and Persistent Mental Illness

IF 3 3区医学 Q2 HEALTH CARE SCIENCES & SERVICES Health Expectations Pub Date : 2024-12-11 DOI:10.1111/hex.70122

Jack C. Collins, Amanda J. Wheeler, Sara S. McMillan, Jie Hu, Sarira El-Den, Helena Roennfeldt, Claire L. O'Reilly

{"title":"Side Effects of Psychotropic Medications Experienced by a Community Sample of People Living With Severe and Persistent Mental Illness","authors":"Jack C. Collins, Amanda J. Wheeler, Sara S. McMillan, Jie Hu, Sarira El-Den, Helena Roennfeldt, Claire L. O'Reilly","doi":"10.1111/hex.70122","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Psychotropic medications are a common treatment modality for people living with severe and persistent mental illness (SPMI). While effective in reducing relapse and hospitalisation, psychotropic medications cause numerous side effects, varying in nature and severity. Identification and management of side effects is crucial in the ongoing management of SPMI.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To characterise the side effects of psychotropic medications, experienced by a sample of consumers living with SPMI, using a validated tool.</p>\n </section>\n \n <section>\n \n <h3> Setting and Participants</h3>\n \n <p>Consumers with SPMI living in the community were recruited from all 25 community pharmacies across four Australian regions, which were allocated to the intervention arm of the Bridging the Gap between Physical and Mental Illness (<i>PharMIbridge</i>) randomised controlled trial (RCT).</p>\n </section>\n \n <section>\n \n <h3> Main Outcome Measures</h3>\n \n <p>Responses to the <i>My Medicines & Me Questionnaire</i> (<i>M3Q)</i>.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Consumers (<i>n</i> = 156) most frequently reported side effects in the categories of sleep-related side effects (80.8%, <i>n</i> = 126), mood-related side effects (75.6%, <i>n</i> = 118) and weight and appetite changes (60.3%, <i>n</i> = 107). Daytime somnolence was the most reported individual side effect (68.6%, <i>n</i> = 107). Mood-related side effects were ranked as the most bothersome, followed by sleep-related side effects and weight and appetite changes. More than one-quarter (29.5%, <i>n</i> = 46) of consumers reported choosing not to take their medications due to side effects. Consumers more frequently told family and friends about the side effects rather than healthcare professionals.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>An overwhelming majority of consumers experienced at least one side effect attributed to their psychotropic medication, with many experiencing multiple. These findings highlight the critical need to regularly engage with consumers to discuss, identify and manage side effects to treatment burden, reduce risk of non-adherence and improve their treatment experience.</p>\n </section>\n \n <section>\n \n <h3> Patient or Public Contribution</h3>\n \n <p>The <i>PharMIbridge</i> RCT included a training programme and intervention service that was co-designed and co-delivered with people with lived experience of mental illness. The research team, expert advisory panel and mentors who supported the delivery and implementation of the training and intervention included participants who have lived experience of mental illness or caring for someone with mental illness.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>ANZCTR12620000577910.</p>\n </section>\n </div>","PeriodicalId":55070,"journal":{"name":"Health Expectations","volume":"27 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632627/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Expectations","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hex.70122","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Psychotropic medications are a common treatment modality for people living with severe and persistent mental illness (SPMI). While effective in reducing relapse and hospitalisation, psychotropic medications cause numerous side effects, varying in nature and severity. Identification and management of side effects is crucial in the ongoing management of SPMI.

Objective

To characterise the side effects of psychotropic medications, experienced by a sample of consumers living with SPMI, using a validated tool.

Setting and Participants

Consumers with SPMI living in the community were recruited from all 25 community pharmacies across four Australian regions, which were allocated to the intervention arm of the Bridging the Gap between Physical and Mental Illness (PharMIbridge) randomised controlled trial (RCT).

Main Outcome Measures

Responses to the My Medicines & Me Questionnaire (M3Q).

Results

Consumers (n = 156) most frequently reported side effects in the categories of sleep-related side effects (80.8%, n = 126), mood-related side effects (75.6%, n = 118) and weight and appetite changes (60.3%, n = 107). Daytime somnolence was the most reported individual side effect (68.6%, n = 107). Mood-related side effects were ranked as the most bothersome, followed by sleep-related side effects and weight and appetite changes. More than one-quarter (29.5%, n = 46) of consumers reported choosing not to take their medications due to side effects. Consumers more frequently told family and friends about the side effects rather than healthcare professionals.

Conclusions

An overwhelming majority of consumers experienced at least one side effect attributed to their psychotropic medication, with many experiencing multiple. These findings highlight the critical need to regularly engage with consumers to discuss, identify and manage side effects to treatment burden, reduce risk of non-adherence and improve their treatment experience.

Patient or Public Contribution

The PharMIbridge RCT included a training programme and intervention service that was co-designed and co-delivered with people with lived experience of mental illness. The research team, expert advisory panel and mentors who supported the delivery and implementation of the training and intervention included participants who have lived experience of mental illness or caring for someone with mental illness.

Trial Registration

ANZCTR12620000577910.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

一群患有严重和持续性精神疾病的社区样本所经历的精神药物副作用。

背景：精神药物是重度持续性精神疾病（SPMI）患者的常用治疗方式。虽然精神药物在减少复发和住院方面有效，但会引起许多副作用，其性质和严重程度各不相同。在SPMI的持续治疗中，副作用的识别和管理至关重要。目的：利用一种经过验证的工具，描述患有SPMI的消费者样本所经历的精神药物的副作用。环境和参与者：生活在社区的SPMI消费者从澳大利亚四个地区的所有25家社区药房招募，这些药房被分配到弥合身心疾病差距（PharMIbridge）随机对照试验（RCT）的干预部门。主要结果测量：对我的药物和我的问卷（M3Q）的回应。结果：消费者（n = 156）最常报告的副作用类别为睡眠相关副作用（80.8%,n = 126）、情绪相关副作用（75.6%,n = 118）和体重和食欲变化（60.3%,n = 107）。白天嗜睡是报告最多的个体副作用（68.6%,n = 107）。与情绪有关的副作用是最令人烦恼的，其次是与睡眠有关的副作用以及体重和食欲的变化。超过四分之一（29.5%,n = 46）的消费者报告说，由于副作用，他们选择不服用药物。消费者更频繁地将副作用告诉家人和朋友，而不是医疗保健专业人员。结论：绝大多数消费者至少经历了一种归因于精神药物的副作用，许多人经历了多种副作用。这些发现突出表明，迫切需要定期与消费者接触，讨论、确定和管理治疗负担的副作用，减少不依从性风险，并改善他们的治疗体验。患者或公众贡献：PharMIbridge RCT包括与有精神疾病生活经历的人共同设计和共同提供的培训计划和干预服务。研究小组、专家咨询小组和导师支持培训和干预的交付和实施，其中包括有精神疾病经历或照顾精神疾病患者的参与者。试验注册号：ANZCTR12620000577910。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Health Expectations 医学-公共卫生、环境卫生与职业卫生

CiteScore

5.20

自引率

9.40%

发文量

251

审稿时长

>12 weeks

期刊介绍： Health Expectations promotes critical thinking and informed debate about all aspects of patient and public involvement and engagement (PPIE) in health and social care, health policy and health services research including: • Person-centred care and quality improvement • Patients'' participation in decisions about disease prevention and management • Public perceptions of health services • Citizen involvement in health care policy making and priority-setting • Methods for monitoring and evaluating participation • Empowerment and consumerism • Patients'' role in safety and quality • Patient and public role in health services research • Co-production (researchers working with patients and the public) of research, health care and policy Health Expectations is a quarterly, peer-reviewed journal publishing original research, review articles and critical commentaries. It includes papers which clarify concepts, develop theories, and critically analyse and evaluate specific policies and practices. The Journal provides an inter-disciplinary and international forum in which researchers (including PPIE researchers) from a range of backgrounds and expertise can present their work to other researchers, policy-makers, health care professionals, managers, patients and consumer advocates.